The research community's rapid acceptance of microarrays notwithstanding, technical challenges remain. Biochip developers continue to grapple with these issues while upgrading their offerings and ...
Companies in the microarray sector are trying to take the technology out of core facilities and put it into the hands of individual researchers by developing technologies such as smaller, less-costly ...
Agencourt Bioscience, a wholly-owned subsidiary of Beckman Coulter (BEC), NuGEN Technologies, and Affymetrix Clinical Services Laboratory announce a collaboration that has yielded a service offering ...
The first study of the use of microarray patches to vaccinate children has shown that the method is safe and induces strong immune responses. The phase 1/2 randomized trial compared results from the ...
- The United States Biomedical Advanced Research and Development Authority (BARDA) has announced Vaxxas will receive US$2 million (AU$3.2 million) as a Concept Stage Winner in its multi-stage $50 ...
The phase 1/2 randomized trial compared results from the measles and rubella vaccine delivered by a microarray patch, a small sticking plaster-like device with an array of microscopic projections that ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback